Iron Chelation Therapy in Transfusion-Dependent Thalassemia

What the review examined

Patients with transfusion-dependent beta-thalassemia (thalassemia major) cannot produce adequate functional hemoglobin and depend on lifelong red-blood-cell transfusions. Because the human body has no regulated pathway to excrete iron, each transfused unit deposits roughly 200-250 mg of iron, and after 10-20 transfusions patients accumulate a toxic body-iron burden. This secondary iron overload is the principal driver of morbidity and mortality, historically causing death from iron-loaded cardiomyopathy in the second or third decade of life.

This clinical review, together with the landmark randomized controlled trials it synthesizes, evaluates the three licensed iron chelators, deferoxamine, deferiprone, and deferasirox, as monotherapy and in combination. It focuses on how each agent removes iron from the two organs that most determine prognosis, the heart and the liver, and on how cardiovascular magnetic resonance (CMR) T2* and R2* imaging have become the pivotal noninvasive tools for quantifying tissue iron and directing therapy.

The three chelators and how they work

Deferoxamine (DFO), the oldest agent, is a hexadentate siderophore originally derived from Streptomyces pilosus; one molecule wraps a single ferric (Fe3+) ion in a stable, excretable complex. Its major limitation is pharmacokinetic rather than chemical: it has a short half-life and poor oral bioavailability, so it must be given by prolonged subcutaneous or intravenous infusion, typically 8-12 hours per day, 5-7 days a week, which heavily burdens adherence.

Deferiprone (DFP) is an orally active bidentate chelator; three molecules coordinate each iron atom. It is notable for efficient penetration into cardiac myocytes, giving it particular strength at removing myocardial iron. Its principal safety concern is agranulocytosis/neutropenia, which mandates regular blood-count monitoring, along with arthropathy and gastrointestinal effects.

Deferasirox (DFX) is a once-daily oral tridentate chelator; two molecules bind each ferric ion. Its convenient dosing has made it a first-line option in many settings. Key adverse effects include rises in serum creatinine and proteinuria (renal), gastrointestinal disturbance, and elevated liver enzymes. When single-agent therapy at maximum dose fails to control a very high iron burden, chelators are combined to exploit complementary tissue distribution and a 'shuttle' effect between the drugs.

Key findings on cardiac and hepatic iron

Because the heart is the organ where iron overload most often proves fatal, the pivotal trials used myocardial T2* (a shorter T2* indicates more iron) as the primary endpoint. In the first randomized comparison of monotherapies, oral deferiprone produced significantly greater improvement in myocardial T2* than subcutaneous deferoxamine over one year (approximately 27% versus 13%), with a correspondingly greater rise in left-ventricular ejection fraction, establishing deferiprone's advantage for clearing cardiac iron.

A placebo-controlled trial of combined deferiprone plus deferoxamine in 65 patients showed that adding oral deferiprone to standard deferoxamine improved myocardial T2*, left-ventricular ejection fraction, and endothelial function beyond deferoxamine alone, supporting intensified combination therapy for significant cardiac siderosis.

The CORDELIA trial (197 patients across 11 countries) compared once-daily oral deferasirox with subcutaneous deferoxamine for myocardial iron removal over one year. Myocardial T2* improved by about 12% with deferasirox versus 7% with deferoxamine, meeting the prespecified noninferiority margin (the trend toward superiority did not reach significance, P = .057). Across the evidence base, all three agents also reduce liver iron concentration and serum ferritin, and normalization of both cardiac and hepatic iron has driven the large historical fall in thalassemia mortality.

Mechanism: from iron overload to organ damage

When transfusional iron saturates transferrin, non-transferrin-bound iron (NTBI) appears in plasma and is taken up avidly by cardiomyocytes, hepatocytes, and endocrine cells through channels such as L-type calcium channels. Inside these cells a redox-active labile iron pool accumulates and, via Fenton chemistry, generates reactive oxygen species that damage mitochondria, lipids, and DNA, producing cardiomyopathy, cirrhosis, diabetes, hypogonadism, and hypothyroidism.

Chelation therapy works by binding both NTBI in the circulation and the intracellular labile iron pool, converting reactive iron into stable complexes that are excreted in urine (deferiprone, and partly deferasirox) or bile/feces (deferasirox, and partly deferoxamine). By lowering the labile iron pool faster than iron re-enters tissue, sustained chelation halts and can reverse oxidative organ injury, which is why continuous exposure and good adherence matter more than peak dosing.

Relevance to the metal-microbiome-disease axis

Iron is the central currency of host-microbe competition, a principle known as nutritional immunity: the host restricts iron to starve pathogens, while microbes deploy siderophores to scavenge it. Systemic iron overload and iron chelation both perturb this balance, which links thalassemia care to the metal-microbiome-disease axis. Excess enteral and systemic iron favors the expansion of siderophilic Enterobacteriaceae and can blunt colonization resistance, whereas restricting iron reshapes microbial community structure.

Chelator chemistry adds a direct microbiological dimension. Deferoxamine is itself a microbial siderophore, and certain pathogens, notably Yersinia enterocolitica and the agents of mucormycosis, can hijack it as a xenosiderophore, an infection risk not shared by the synthetic oral chelators deferiprone and deferasirox. Deferasirox conversely shows antimicrobial and antifungal activity by depriving microbes of iron. These observations position iron chelation not only as organ-protective iron removal but as a modulator of the host iron economy that governs the microbiome, consistent with the broader thesis that metal handling shapes microbial ecology and, through it, disease susceptibility. This microbiome linkage in thalassemia remains an emerging, mechanistically plausible area rather than a settled clinical outcome.